|
|
| MedChemExpress (MCE) 提供多元的高品質研究化學品和生物化學品，包括超過 40,000 種用於實驗室和科學用途的新型生物活性化合物、染劑、胜肽和天然化合物。 |
|
CAS No.: 1398695-47-0
|
|
|
|
|
Research Area: SYK Inhibitor/Inflammatory Skin Disease
|
|
|
|
•
|
A selective and skin permeable spleen tyrosine kinase (Syk) inhibitor with a pIC50 of 7.1, and exhibits >300-fold selectivity over Aurora B.
|
|
•
|
Has the potential for chronic spontaneous urticaria, cold urticaria, and cutaneous lupus erythematosus research.
|
|
|
|
Solubility: DMSO : 50 mg/mL (133.52 mM; ultrasonic and warming and heat to 60°C)
|
|
|
CAS No.: 2406278-81-5
|
|
|
|
|
Research Area: Tankyrase Inhibitor/Colon Cancer
|
|
|
|
•
|
A potent, orally active Tankyrase 1 and Tankyrase 2 (TNKS1/TNKS2) inhibitor with IC50 values of 13 nM and 2 nM, respectively.
|
|
•
|
Shows inhibition of Wnt/β-catenin signaling and proliferation in COLO 320DM cells or in COLO 320DM mouse colon carcinoma xenografts.
|
|
•
|
Demonstrates antitumor efficacy in COLO 320DM mouse colon carcinoma and B16-F10 mouse melanoma models.
|
|
|
|
Solubility: DMSO : 100 mg/mL (196.26 mM; Need ultrasonic)
|
|
|
CAS No.: 2102192-68-5
|
|
|
|
|
Research Area: PD-L1 Antibody/Advanced Solid Tumors
|
|
|
|
•
|
A fusion protein of a humanized single-domain anti-PD-L1 antibody fused with a human IgG1 Fc fragment.
|
|
•
|
Blocks interaction between PD-L1 and PD-1, resulting in T cell-mediated immune response to neoplasms.
|
|
•
|
Used in the research of advanced solid tumors, biliary tract carcinoma and sarcoma.
|
|
|
|
Solubility: Solution: 9.8 mg/mL
|
|
|
CAS No.: 1517965-94-4
|
|
|
|
|
Research Area: OX1R/OX2R Antagonist/Insomnia and Sleep Apnoea Syndrome
|
|
|
|
•
|
An orally active, dual OX1R and OX2R antagonist with IC50 values of 1.05 nM and 1.27 nM, respectively.
|
|
•
|
Exhibits potent sleep-promoting effects in a rat polysomnogram study, and optimal pharmacokinetic properties with rapid Tmax and short half-lives are observed in rats and dogs.
|
|
|
|
Solubility: DMSO : ≥ 100 mg/mL (223.48 mM)
|
|
|
CAS No.: 2784577-71-3
|
|
|
|
|
Research Area: RXFP3 Antagonist/Metabolic Syndrome
|
|
|
|
•
|
Selective and CNS-penetrant relaxin family peptide 3 (RXFP3) non-peptide antagonist.
|
|
•
|
Inhibits relaxin-3-induced ERK1/2 phosphorylation, and decreases cAMP accumulation.
|
|
•
|
Blocks the stimulation of food intake induced by the RXFP3-selective agonist R3/I5 in rats.
|
|
|
|
Solubility: DMSO : 125 mg/mL (270.04 mM; Need ultrasonic)
|
|
|
MCE海洋天然產品:
|
|
|
|
|
近年來，海洋天然物質已成為發現新藥的重要來源，例如:抗病毒藥物 Vidarabine 以及抗腫瘤藥物 Cytarabine 是由海綿中分離出的spongothymidine和spongouridine、 用於治療乳腺癌和脂肪肉瘤的 Eribulin 是來自 Halichondria okadai Kadota的 Halichondrin B 衍生物。
|
|
Product Name
|
Description
|
Structure
|
|
Didemnin B
|
Shows activity against miirine B16 melanoma, P388 leukemia, and M5076 sarcoma.
|
|
|
Aaptamine
|
A competitive antagonist of α-adrenoceptor.
|
|
|
Jasplakinolide
|
A potent actin polymerization inducer with fungicidal and anti-cancer activities.
|
|
|
Aeroplysinin 1
|
Exerts anti-HIV-1, anti-inflammatory, anti-angiogenic and anti-tumor activities.
|
|
|
Psammaplin A
|
A potent inhibitor of HDAC and DNA methyltransferases.
|
|
|
|
|
|
MCE可提供magnetic beads 和agarose beads:
|
|
|
|
|
|
|
|
最新文獻引用MCE產品
|
|
|
Nature.
2022 Nov;611(7936):603-613.
|
|
|
|
Cell.
2022 Nov 10;185(23):4361-4375.e19.
|
|
|
|
Nat Genet.
2022 Nov;54(11):1702-1710.
|
|
|
|
Cancer Discov.
2022 Nov 4:CD-22-0535.
|
|
|
|
|
|
|
